SCHEMBL4360748

SCHEMBL4360748

N#Cc1ccccc1C1=C2C=NC=C[N+]2(N)C(c2ccc(Oc3ccccc3)cc2)=N1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNK2 Q07912 1/20 0.40
ALDH1A1 P00352 3/20 0.34
HPGD P15428 3/20 0.34
ERBB2 P04626 1/20 0.34
NAAA Q02083 1/20 0.32
CHEK2 O96017 1/20 0.32
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
KDM4E B2RXH2 1/20 0.32
MAPT P10636 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
PRKCQ Q04759 1/20 0.32
ESR2 Q92731 1/20 0.32
FFAR1 O14842 1/20 0.31
AKR1B1 P15121 1/20 0.31
RAF1 P04049 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4362605 0.86 CHEK2 (0.39) TNK2ERBB2NAAACHEK2CYP1A2
SCHEMBL4352096 0.86 TNK2 (0.36) TNK2CHEK2
SCHEMBL1131147 0.84 NPC1 (0.34) TNK2CHEK2
SCHEMBL1130366 0.81 POLB (0.37) TNK2KDM4ESMN1; SMN2
SCHEMBL4352081 0.81 MAOA (0.43) TNK2ALDH1A1CHEK2MEN1KMT2A
SCHEMBL4357979 0.80 LTA4H (0.42) TNK2ALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL4363018 0.80 LTA4H (0.42) TNK2MEN1KMT2AESR2
SCHEMBL4353437 0.80 MAPK14 (0.36) TNK2SMN1; SMN2
SCHEMBL1129520 0.78 TNK2 (0.33) TNK2CHEK2
SCHEMBL4540501 0.77 TNK2 (0.37) TNK2CHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8481733-B2 Substituted imidazopyr- and imidazotri-azines OSI Pharmaceuticals, LLC (US) 2013-07-09 US claimed
EP-2283020-B1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARM INC (US) 2012-10-31 EP claimed
US-8481733-B2 Substituted imidazopyr- and imidazotri-azines OSI Pharmaceuticals, LLC (US) 2013-07-09 US disclosed
EP-2283020-B1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARM INC (US) 2012-10-31 EP disclosed
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES OSI PHARMACEUTICALS, INC. (US) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES ABL1, TPMT, CYP2C19 TNK2 2837/4885ALDH1A1 292/4885HPGD 1283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.